At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
Avelumab (MSB0010718C) +1 moredrug
Likely dose
Avelumab (MSB0010718C) 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AN OPEN LABEL, SINGLE ARM PHASE 1B STUDY OF AVELUMAB PLUS AXITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
In Brief
A Phase 1 clinical trial evaluating Avelumab (MSB0010718C) and Axitinib (AG-013736) for Carcinoma, Hepatocellular. Completed, enrolled 22 participants across 7 sites.
Detailed Summary
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedSep 2017
Primary CompletionAug 2019
Study CompletionOct 2019
TodayJul 2026
First PostedSep 21, 2017
Enrollment StartSep 8, 2017
Primary CompletionAug 27, 2019
Study CompletionOct 25, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.8 years ago
Interventions
Avelumab (MSB0010718C)drug
Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
Axitinib (AG-013736)drug
Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.